TICKERNERD
Menu
EWTXEWTXHealthcare · Biotechnology

EWTX Stock Forecast: Edgewise Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 24 Aug 2026
$45
+1.22% on the day

The 13 Wall Street analysts covering Edgewise Therapeutics, Inc. hold a median 12-month price target of $52 — +16.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 51 of 100 as at 22 Aug 2026 — in the upper half.

Market cap
$4.8B
Ticker Nerd rank
51 / 100
Median analyst target
$52
Analysts covering
13
Revenue$0.0
Operating income−$61.9M
Net income−$57.3M
Free cash flow−$42.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+1.5%
1M
+9.5%
YTD
+80.2%
1Y
+201.1%
From 52W high
−7.5%
From 52W low
+226.4%
$14
$48
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

EWTX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Edgewise Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
51 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
90
Value
81
Accruals
75
Quality
50
Issuance
46
Volatility
39
Revisions
36
Growth
31
Size
25

Momentum (90): The shares have been drifting up relative to others.

Growth (31): Sales and profits are flat, shrinking, or growing more slowly than they were.

Size (25): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

EWTX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on EWTX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50$60$70Oct 25Jan 26Apr 26Jul 26EWTXHigh $66Median $52Low $36

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says13 analysts
11 Buy2 Hold0 Sell
Low $36Median $52High $66

The green dot is the last close — the median target sits +16.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
20 Aug 2026JP MorganMaintainsOverweight$53 → $60
11 Aug 2026Goldman SachsMaintainsNeutral$32 → $36
11 Aug 2026Goldman SachsMaintainsNeutral—
20 July 2026Evercore ISI GroupMaintainsOutperform—
20 July 2026Evercore ISI GroupMaintainsOutperform$45 → $55
9 July 2026OppenheimerInitiatesOutperform$51
9 July 2026OppenheimerInitiatesOutperform—
6 July 2026GuggenheimMaintainsBuy$41 → $51
6 July 2026GuggenheimMaintainsBuy—
17 June 2026Goldman SachsMaintainsNeutral—
17 June 2026RBC CapitalMaintainsOutperform—
16 June 2026HC Wainwright & Co.ReiteratesBuy—
2 June 2026HC Wainwright & Co.MaintainsBuy—
2 June 2026RBC CapitalMaintainsOutperform—
2 June 2026WedbushMaintainsOutperform—
17 Mar 2026JP MorganMaintainsOverweight—
17 Mar 2026WedbushReiteratesOutperform—
27 Feb 2026Evercore ISI GroupMaintainsOutperform—
14 Nov 2025JP MorganMaintainsOverweight—
7 Nov 2025RBC CapitalMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. EWTX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

EWTX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 24 Aug 2026, Edgewise Therapeutics, Inc. returned +201.1% against +19.6% for the S&P 500, dividends included.

EWTX vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250300Oct 25Jan 26Apr 26Jul 26EWTXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

EWTX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Edgewise Therapeutics, Inc. (EWTX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−27.1×

Cheaper than 97% of US stocks

Price / sales
—
Price / book
10.6×

Cheaper than 10% of US stocks

EV / EBITDA
−20.0×

Cheaper than 89% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−38.0%

Higher than 25% of US stocks

Return on assets
−25.0%

Higher than 17% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Edgewise Therapeutics, Inc. (EWTX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Edgewise Therapeutics, Inc. has a market value of $4.8B and an enterprise value of $4.3B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$197.2M.

  • Diluted earnings per share, trailing twelve months: $−1.85.

  • Free cash flow in the twelve months to 30 June 2026: −$158.8M.

  • Shares outstanding: 107.8M.

  • Trailing P/E: −27.1×; forward P/E: −24.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Edgewise Therapeutics, Inc. employs 127 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 25 Aug 2026

Data provided by Twelve Data

Peers

EWTX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
EWTXEdgewise Therapeutics, Inc.$4.8B
51
DYNDyne Therapeutics, Inc.$4.8B
29
PBLSParabilis Medicines, Inc.$4.7B
0
CELCCelcuity, Inc.$4.6B
30
ACADACADIA Pharmaceuticals, Inc.$5.0B
82
ELVNEnliven Therapeutics, Inc.$4.3B
68
MANEVeradermics, Inc.$4.2B
2

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Edgewise Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest EWTX news & analysis

Edgewise Therapeutics Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026

PRNewsWire · 24 Aug 2026positive

Edgewise Therapeutics announced that an abstract from its Phase 2 CIRRUS-HCM trial of EDG-7500 in hypertrophic cardiomyopathy was selected for a late-breaking science presentation at the European Society of Cardiology Congress, to be held August 28-31 in Munich, Germany. The presentation will highlight positive top-line 12-week data from the trial in obstructive and nonobstructive HCM.

Why it matters — The ESC late-breaking presentation gives EWTX watchers a high-profile forum for the company's positive Phase 2 data on its lead cardiovascular candidate EDG-7500.

Edgewise Therapeutics: The Servier Deal Creates A Self-Funded Cardiovascular Platform

Seeking Alpha · 18 Aug 2026positive

Edgewise Therapeutics completed a $1.55 billion sale of sevasemten to Servier, becoming a well-capitalized cardiovascular drug developer. Its lead asset EDG-7500 showed robust Phase 2 efficacy in obstructive and nonobstructive HCM, and the company's cash runway now extends into the early 2030s, with up to $1.1 billion in milestone upside retained.

Why it matters — The Servier deal provides Edgewise with extended funding for late-stage pipeline development without shareholder dilution, strengthening its position as a cardiovascular platform.

Edgewise Therapeutics Reports Second Quarter 2026 Financial Results

PRNewsWire · 6 Aug 2026positive

Edgewise Therapeutics reported its second quarter 2026 financial results, announcing positive top-line data from the 12-week Phase 2 CIRRUS-HCM trial of EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy. The company also completed the sale of sevasemten and its muscular dystrophy business to Servier for up to $2.65 billion in July 2026.

Why it matters — A EWTX watcher would care because the company reported positive Phase 2 data for its lead cardiovascular candidate and completed a major divestiture that strengthens its balance sheet and sharpens focus on the cardiovascular pipeline.

FAQ

Frequently asked questions about EWTX stock

What is the EWTX stock price forecast for 2026-2027?

The 13 Wall Street analysts covering Edgewise Therapeutics, Inc. have a median 12-month price target of $52, with estimates ranging from $36 to $66. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is EWTX stock a buy right now?

Of the 13 analysts covering Edgewise Therapeutics, Inc., 11 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Edgewise Therapeutics, Inc. 51 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank EWTX?

As at 22 Aug 2026, Edgewise Therapeutics, Inc. ranks 51 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (90 of 100).

Will EWTX stock go up?

No one can know that. What the data says: the median 12-month target from 13 analysts implies +16.3% from the last close, and Ticker Nerd's factor model ranks Edgewise Therapeutics, Inc. 51 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the EWTX stock forecast for 2030?

No analyst covering Edgewise Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for EWTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $36 to $66 over the next 12 months.

How has EWTX stock performed over the past year?

Edgewise Therapeutics, Inc. returned +201.1% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Edgewise Therapeutics, Inc. do?

Edgewise Therapeutics Inc. is a biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative therapies targeting rare muscle disorders.

What is the latest news on EWTX?

The most recent item we track (PRNewsWire, 24 Aug 2026): "Edgewise Therapeutics Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026". Edgewise Therapeutics announced that an abstract from its Phase 2 CIRRUS-HCM trial of EDG-7500 in hypertrophic cardiomyopathy was selected for a late-breaking science presentation at the European Society of Cardiology Congress, to be held August 28-31 in Munich, Germany. The presentation will highlight positive top-line 12-week data from the trial in obstructive and nonobstructive HCM.

Company

About Edgewise Therapeutics, Inc.

Edgewise Therapeutics Inc. is a biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative therapies targeting rare muscle disorders. The company's primary function is to address unmet medical needs in the area of muscular health, specifically aiming to develop treatments for conditions such as Duchenne muscular dystrophy. Edgewise Therapeutics employs a cutting-edge approach by utilizing small molecule drugs to modulate proteins critical to muscle function and health. Operating within the biopharmaceutical industry, Edgewise is part of a niche sector where advancements can lead to significant improvements in patient care. Their efforts contribute to the broader medical and pharmaceutical markets by potentially offering new therapeutic options that can have a profound impact on patients' lives. Market significance is underscored by the ongoing need for effective treatments for rare diseases, which often lack adequate therapeutic solutions. Edgewise Therapeutics is an example of how specialized research and development can drive innovation in healthcare, seeking to transform scientific advancements into life-changing medications.

CEO Dr. Kevin Koch Ph.D. · 127 employees · United States · https://edgewisetx.com